

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT***(Use as many sheets as necessary)***Complete if Known**

Application Number	10/604,945
Filing Date	August 27, 2003
First Named Inventor	Itzhak Bentwich
Art Unit	3629
Examiner Name	NGUYEN, TAN D
Attorney Docket Number	050992.0300.05USCP

Sheet 1 of 2

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	C1870	Doench JG and Sharp PA. Genes Dev, 2004;18(5):504-11.	
	C1880	ENRIGHT AJ, MicroRNA targets in Drosophila, Genome Biology 2003;5:R1.	
	C1890	LEWIS BP, Prediction of Mammalian MicroRNA Targets, Cell 2003;115:787-98.	
	C1900	STARK A, Identification of Drosophila MicroRNA Targets, PLoS Biology 2003;1(3):397-409.	
	C1910	LAI EC, Predicting and validating microRNA targets, Genome Biology 2004;5:115.	
	C1920	VELLA MC, Architecture of a validated microRNA::target interaction, Chemistry & Biology 2004;11:1619-23.	
	C1930	BRENNECKE J, Principles of MicroRNA-target recognition, PLoS Biology 2005;3(3):e85.	
	C1940	MACMILLAN AM, Dynamic association of proteins with the pre-mRNA branch region, Genes & Development 1994;8:3008-20.	
	C1950	DAS BK, Characterization of a protein complex containing spliceosomal proteins SAPs 49,130, 145, and 155, Mol Cell Biol 1999;19(10):6796-802.	
	C1960	GOLAS MM, Molecular architecture of the multiprotein splicing factor SF3b, Science 2003;300:980-3.	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO:**

Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT***(Use as many sheets as necessary)***Complete if Known**

Application Number	10/604,945
Filing Date	August 27, 2003
First Named Inventor	Itzhak Bentwich
Art Unit	3629
Examiner Name	NGUYEN, TAN D
Attorney Docket Number	050992.0300.05USCP

Sheet

2

of

2

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	C1970	LOPEZ AJ, Alternative splicing of pre-mRNA: developmental consequences and mechanisms of regulation. Annu Rev Genet 1998;32:279-305.	

Examiner
SignatureDate
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO:****Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.